Pharmacyclics, Inc. (NQ: PCYC)
89.75 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(PCYC) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 19, 2014
(Jutia Group, 2/12/14)
[Reuters] - U.S. health regulators on Wednesday approved the Johnson & Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic...(read more)
(Stock Blog Hub, 8/19/13)
Synageva BioPharma Corp. (GEVA) recently announced that it has received breakthrough therapy designation from the US Food and Drug Administration...(read more)
(Stock Blog Hub, 4/21/13)
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus...(read more)
Pharmacyclics (PCYC) Company Overview

There is no analysis for PCYC yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here